Evidence map›Paper›PMID 35471148›Full record

ArticleCell cycle (Georgetown, Tex.)2022

CBX3 regulated by miR-139 promotes the development of HCC by regulating cell cycle progression.

Pan Zhang, Xiaoyan Yang, Zhongming Zha, Yumeng Zhu, Guoqiang Zhang, Guotao Li

Open access · hybridAbstract read
In one paragraph

Article in Cell cycle (Georgetown, Tex.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Pan ZhangDepartment of Infectious Diseases, Luoyang Central Hospital Affiliated to Zhengzhou University, Luoyang, Henan, China.
Xiaoyan YangDepartment of Infectious Diseases, Luoyang Central Hospital Affiliated to Zhengzhou University, Luoyang, Henan, China.
Zhongming ZhaDepartment of Hepatobiliary Surgery, Luoyang Central Hospital Affiliated to Zhengzhou University, Luoyang, Henan, China.
Yumeng ZhuDepartment of Infectious Diseases, Luoyang Central Hospital Affiliated to Zhengzhou University, Luoyang, Henan, China.
Guoqiang ZhangDepartment of Infectious Diseases, Luoyang Central Hospital Affiliated to Zhengzhou University, Luoyang, Henan, China.
Guotao LiDepartment of Infectious Diseases, Luoyang Central Hospital Affiliated to Zhengzhou University, Luoyang, Henan, China.
Luoyang Central Hospital Affiliated to Zhengzhou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC), a major primary liver cancer, is one of the most lethal malignancies worldwide. Increasing evidence has demonstrated that chromobox protein homolog 3 (CBX3) functions as an oncogene in different cancers. However, its expression profiles and biological functions in HCC remain unknown. Data on CBX3 expression in HCC acquired from the GEO and TCGA databases were analyzed. The biological functions of CBX3 in HCC were examined by in vitro experiments. Bioinformatics analysis, qRT-PCR and western blotting were performed to explore the mechanism of CBX3 in HCC. CBX3 mRNA was upregulated in HCC tissues, and overexpression of CBX3 mRNA was negatively correlated with malignancies and poor prognosis in HCC patients. CBX3 knockdown decreased growth, migration and invasion of HCC cells in vitro. Moreover, bioinformatics analysis and experimental observation indicated that CBX3 expression was correlated with cell cycle regulatory proteins in HCC cells. Finally, starBase predicted that miR-139 could directly target CBX3 in HCC. Confirmatory experiments verified that miR-139 overexpression attenuated HCC cell proliferation and migration, and these effects could be reversed by overexpressing CBX3. Our results showed that the miR-139/CBX3 axis may be involved in HCC development by regulating cell cycle progression and may be a promising target in the treatment of HCC.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsMicroRNAsCell DivisionCell Line, TumorCell MovementCell ProliferationChromosomal Proteins, Non-HistoneGene Expression Regulation, NeoplasticHumansRNA, MessengerCBX3 protein, humanChromosomal Proteins, Non-HistoneMicroRNAsMIRN139 microRNA, humanRNA, MessengerCBX3cell cycle progressionHCCmiR-139

Identifiers

PMID35471148
PMCPMC9302499
OpenAlexW4224942923

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.